Should Gilead Sciences Be Worried About Allergan?

Should Gilead Sciences Be Worried About Allergan?


That's what another liver disease, non-alcoholic steatohepatitis , has been called. The global market for NASH drugs could be $40 billion annually -- and there are no approved treatments for the disease.



from Biotech News